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Summary 
Chronic stress is an important risk factor for atherosclerosis, which is a chief 
process in the development of cardiovascular disease. Increased circulating levels of 
corticosterone have been documented in several animal models of chronic stress. 
However, it remains to be established whether corticosterone is sufficient to exacerbate 
atherosclerosis. To test this hypothesis, apolipoprotein E (ApoE)-deficient mice were 
fed a high-fat diet for 13 weeks with exposure to either corticosterone or vehicle in the 
drinking water (CORT and Con). Corticosterone treatment significantly increased 
atherosclerotic plaque area at the aortic root. Such exacerbation of atherosclerosis was 
accompanied by significantly lower levels of circulating white blood cells and serum 
interleukin- (IL-1), and significantly elevated serum concentrations of total 
cholesterol, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and 
small dense low-density lipoprotein (sd-LDL) in CORT mice when compared to Con 
mice. These findings demonstrate that corticosterone is sufficient to exacerbate 
atherosclerosis in vivo despite its anti-inflammatory properties and that this marked 
pro-atherogenic phenotype is primarily associated with increased dyslipidaemia.  
3 
 
 
Keywords: stress, dyslipidaemia, cholesterol, Hypothalamic-pituitary-adrenal axis, 
apoE-deficient mice. 
  
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Introduction 
Atherosclerosis is a chief process in the development of cardiovascular disease 
(CVD), which is the leading cause of mortality in both developed
 
and developing 
countries 1. Several modifiable risk factors have been associated to CVD 2-4 with stress 
being an important contributor to atherosclerosis 
5
. Indeed, it has been documented that 
chronic and/or repeated exposure to stressful stimuli leads to endothelial dysfunction
 
and atherosclerosis 
6
. Stressful conditions are known to activate the 
hypothalamic-pituitary-adrenal axis (HPA axis) inducing increases in circulating 
catecholamines and glucocorticoids; thus the development of CVD may result from 
certain pathophysiological effects of these hormones. In that sense, several studies have 
documented a correlative link between synthetic, as well as endogenous glucocorticoids, 
and atherosclerosis. Chronic synthetic glucocorticoid treatment (e.g. prednisone) is 
commonly prescribed in autoimmune diseases such as rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE) and was found to be associated with 
atherosclerosis progression in both RA and SLE patients 
7-10
. Unfortunately, the stage of 
disease progression in RA and SLE patients 
8
 coupled with the synthetic nature of 
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glucocorticoids used, which have higher affinities for glucocorticoid receptors 
11, 12
 and 
longer half-life 
13
, are important confounding factors in assessing a potential role of 
endogenous, or natural, glucocorticoids in atherosclerosis. Accelerated atherosclerosis 
has also been reported in patients with Cushing’s Syndrome (CS), a hormonal disorder 
caused by excessive levels of the endogenous glucocorticoid cortisol 
14
. However, 
several other important CVD risk factors such as visceral obesity, hypertension, insulin 
resistance and dyslipidaemia are commonly observed in patients with CS 
15, 16
 and are 
also confounding factors in establishing a causal relationship between natural 
glucocorticoids and atherosclerosis. Therefore, it remains to be established whether 
chronic exposure to elevated levels of natural glucocorticoids is sufficient to induce or 
accelerate atherosclerosis. 
Several animal models of chronic stress or depression including forced swimming, 
restraint, and psychosocial stress have been shown to increase circulating levels of 
corticosterone 
17-20
. Other studies have demonstrated that corticosterone administration 
is a valid model to study chronic stress in animals 
20-22
. Therefore, in the present study 
we hypothesized that chronic administration of low levels of the natural glucocorticoid 
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corticosterone exacerbates atherosclerosis in Apolipoprotein E (ApoE)-deficient mouse, 
an animal model frequently used in atherosclerosis research due to the development of 
plaques of similar type and distribution in comparison to humans 
23, 24
.  
 
Materials and Methods 
Animals and diet 
Male ApoE-deficient (B6.KOR/StmSlc-Apoe
shl
) mice (6 weeks old) from the Japan SLC, Inc 
(Shizuoka, Japan) were housed individually and maintained in light- (12:12-h light-dark
 
cycle) 
and temperature-controlled quarters (22°C) 
25, 26
.Mice were acclimated to the animal facilities 
while being fed normal chow for one week. High-fat diet feeding (21% fat; Oriental Yeast, 
Tokyo, Japan) was then initiated at 7 weeks of age 
27, 28
. At this point mice were randomly 
assigned into control or corticosterone groups and monitored until sacrifice. The study protocol 
was reviewed and approved by the Committee on the Ethics of Animal Experiments at Waseda 
University, Japan.  
 
Corticosterone treatment 
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The corticosterone group (CORT: n=8) was treated with corticosterone dissolved in 
drinking water for 13 weeks. Corticosterone was first dissolved in 30% (w/v) 
2-hydroxypropyl--cyclodextrin (HBC) and then diluted to 25 g/ml with distilled 
water. The final concentration of HBC in the drinking water was 0.6%. The control 
group of mice (Con: n=8) was treated with vehicle (i.e. 0.6% HBC in drinking water). 
The period of 13 weeks of intervention was used because previous studies have 
documented that ApoE-deficient mice develop atherosclerotic plaques after 12 weeks of 
exposure to high-fat diet 
27
. Water and food intake were monitored throughout the 
experiment. Based on daily water intake, the dose of corticosterone was ~177 g/day, or 
8.4 mg/kg body weight, in the beginning of the study. This dose was previously shown 
to restore low physiological levels of corticosterone in adrenalectomized male mice 
29
, 
and was 1/5 or less of doses used in previous chronic studies 
20-22
. Despite the weight 
gain in animals of both groups during the study, water intake was unaffected. As a result 
the daily corticosterone dose was continuously reduced down to ~3.8mg/kg at the last 
week of intervention (i.e. ½ of the initial dose). This treatment did not elicit any clear 
behavioral changes that could be observed during the daily monitoring of animals. 
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Tissue Preparation and Quantification of Atherosclerosis 
Tissue preparation was performed as previously described 
30
. Briefly, once mice were 
anesthetized with sevoflurane, blood was collected with and without heparin from the 
axillary artery for leukocyte and monocyte cell counting and serum lipid profiling. Mice 
were then perfused with PBS, and then the heart was harvested and fixed with 4% 
paraformaldehyde. Animals were then sacrificed by cervical dislocation and the 
gastrocnemius muscle was collected and weighted. Processing of fixed tissue then 
proceeded with exposure to sequential increasing grades of sucrose/PBS (10%, 15% and 
20%), before samples were quickly frozen in Tissue-Tek OCT compound (Sakura 
Finetek Japan, Tokyo, Japan). Atherosclerotic plaque quantification was performed as 
previously described 
30
. Basically, cross sections of 6m of the aortic root were stained 
with freshly prepared Oil Red O working solution, rinsed with distilled water and 
counterstained with Mayer’s hematoxylin. Sections were then rinsed again with distilled 
water and mounted into slides with glycerol-based mounting medium. Images were 
acquired with a digital camera (Nikon, Tokyo, Japan) coupled to a Nikon TE2000 
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microscope. Areas of atherosclerotic plaques in five sections (at least 60m apart) from 
each mouse were analyzed and quantified with Image J (NIH, Bethesda, MD, USA) and 
the average of those was considered representative of that animal and used for further 
analysis.   
 
Total and differential white blood cell count and serum lipid profile  
Total and differential white blood cells were counted in each heparinized blood sample 
using a SF-3000 (Sysmex, Kobe, Japan). The concentrations of total cholesterol, 
triglycerides (TG), chylomicron (CM), high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), small dense low-density lipoprotein (sd-LDL), and very-low-density 
lipoprotein (VLDL) were analyzed in 60μL of serum as previously described 31 using a 
HPLC based on-line
 
dual enzymatic method for simultaneous quantification of 
cholesterol
 
and triglycerides. This analysis was performed at Skylight Biotech Inc. 
(Akita, Japan).  
 
Measurement of serum interleukin-1interleukin-6 and CCL2  
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Serum concentrations of interleukin-1IL-1interleukin-6 (IL-6) and monocyte 
chemotactic protein-1(MCP-1/CCL2) were measured by enzyme linked immunosorbent 
assay (ELISA) (Quantikine R&D Systems, Minneapolis, MN, USA). All assays were 
performed in a microplate reader (VERSAmax, Molecular Devices, Sunnyvale, CA, 
USA) according to the manufacturer instructions.  
 
Statistical analysis 
All data are presented as mean ± SEM. Values were compared by unpaired t-tests 
performed with the StatView software (SAS Institute, Cary, NC). A value of p<0.05 was 
considered statistically significant.  
 
Results  
Both CORT and Con mice had approximately doubled their body weight (BW) by the 
end of the study, with no significant difference in either BW or food intake between 
groups (Figures 1A, B). However, chronic low dose corticosterone treatment led to a 
significant reduction in gastrocnemius muscle weight (P<0.01) (Figure 1C). This 
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finding demonstrates that increased levels of the natural glucocorticoid corticosterone 
causes skeletal muscle atrophy similarly to the use of synthetic glucocorticoids (e.g. 
dexamethasone) 
32
. Atherosclerotic plaque lesions at the aortic root were 77% larger in 
CORT mice compared with Con mice denoting a profound exacerbation of 
atherosclerosis by corticosterone (P<0.05) (Figure 1D, E). Of note, several variables 
suggest that the significant impact of corticosterone on the development of 
atherosclerosis was not linked to increased systemic inflammation. First, total 
circulating white blood cell and neutrophil numbers in CORT mice were 29% and 24% 
lower than in Con mice, respectively (P<0.05, Figure 2A). Second, no significant 
differences were observed in lymphocyte, monocyte, eosinophils or basophils between 
groups (Figure 2A). Third, IL-1 serum levels in CORT mice were 55% lower than the 
ones observed in Con mice (P<0.05), while IL-6 and CCL2 levels were similar between 
groups (Figure 2B). On the other hand, mice chronically treated with corticosterone 
were severely dyslipidaemic. Although no differences were observed between groups in 
relation to triglycerides, chylomicron and HDL levels, significantly elevated serum 
levels of total cholesterol, LDL, VLDL and sd-LDL were present in CORT mice in 
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comparison to Con mice (i.e. by 51%, 35%, 67% and 32%, respectively, P<0.05, Figure 
3).  
 
Discussion 
The findings presented here clearly demonstrate that chronic low dose corticosterone 
treatment exacerbates atherosclerosis in association with dyslipidaemia, despite having 
systemic anti-inflammatory effects. Although epidemiological studies have previously 
linked increased stress levels with the development of CVD 
5
, it is difficult to isolate the 
precise contribution of stress per se from its influence on other CVD risk factors, such 
as the ones associated with environmental factors (e.g. eating habits). A more causal 
link between stress and atherosclerosis was first established by Kumari et al., who 
observed that ApoE-deficient mice exposed to chronic stress for 12 weeks presented 
3-fold increases in atherosclerosis in association with ~10-fold elevation in circulating 
corticosterone levels 
33
. Nevertheless, it remained to be established whether the natural 
glucocorticoid corticosterone was sufficient to induce an atherogenic phenotype and 
what systemic effects would be associated with this phenomenon. To address these 
13 
 
questions and minimize adverse effects of chronic glucocorticoid administration, we 
opted to study ApoE-deficient mice fed a high-fat diet with or without exposure to a low 
dose of corticosterone in the drinking water for 13 weeks. In spite of the limitation of 
not assessing circulating levels of corticosterone during the study, we believe our model 
induced much lower increases in serum corticosterone than observed by Kumari et al. 
33
 
for a couple of reasons. First, our initial dose of ~8.4mg/kg of body weight was 
previously shown to restore circulating corticosterone to only low physiological levels 
in adrenalectomized male mice 
29
. Second, the required high-fat diet content (i.e. 21%) 
to induce atherosclerotic plaque formation in ApoE-deficient mice within the 13 week 
time frame 
27
 caused drastic body weight increases in both CORT and Con mice, 
without altering water consumption. Therefore, the daily corticosterone dose 
administered in the drinking water was ~3.8mg/kg of body weight at the end of the 
intervention. It is important to note that endogenous glucocorticoid production tends to 
decrease secondary to a suppression of HPA axis upon exogenous glucocorticoid 
treatment 
34
. In our study, measurement of endogenous glucocorticoid levels was not 
feasible due to insufficient volume of blood in these mice. Despite this limitation, 
14 
 
increased atherosclerosis was observed in CORT mice (i.e. 80%) suggesting a role for 
corticosterone in accelerating atherosclerosis.  
Obesity is widely recognized as an important risk factor for CVD 
2, 3
 that leads 
initially to local adipose tissue inflammation and then systemic low-grade inflammation 
35-38
. In fact, systemic low-grade inflammation is a common feature of not only obesity, 
but also type 2 diabetes and cardiovascular disease 
3, 39, 40
. CORT mice likely gained 
more fat mass than Con mice because only the CORT group presented significant 
muscle atrophy, despite increasing body weight to the same extent as Con mice 
throughout the intervention. Regardless, there was no evident exacerbation of low-grade 
systemic inflammation in CORT mice, as circulating white blood cells and IL-1β were 
significantly reduced by corticosterone. These findings support a predominant 
anti-inflammatory effect of corticosterone in mice. It is important to note, however, that 
an exacerbated inflammatory state could be present at the atherosclerotic plaques of 
CORT mice. In that case, our data suggests that this phenomenon would be resulting 
from the atherosclerotic process itself, rather than being a secondary effect of obesity 
and low-grade systemic inflammation. Actually, the effective use of glucocorticoids to 
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control inflammation in autoimmune diseases such as RA and SLE, despite being 
associated with exacerbation of atherosclerosis 
7-10
, provides further circumstantial 
evidence for this notion.  
Dyslipidaemia is another critical risk factor for CVD 
41
. Here, we found that 
corticosterone caused significant increases in total cholesterol, LDL, VLDL and 
sd-VLDL cholesterol, which are easily absorbed into the vascular endothelium, and are 
susceptible to oxidative modifications, thereby enhancing atherosclerosis 
42
. Although 
the mechanisms by which corticosterone interferes in cholesterol metabolism is beyond 
the scope of this study, synthetic glucocorticoid treatment has been shown to increase 
the expression of the enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA 
reductase) both in vivo and in vitro 
43-45
. HMG-CoA reductase is a key regulatory 
enzyme in the conversion of HMG-CoA to mevalonic acid, which is a precursor for 
cholesterol synthesis 46. Competitive inhibitors of HMG-CoA reductase (e.g., Statins) 
increase the expression of LDL receptors in the liver, which in turn decreases serum 
total cholesterol and LDL cholesterol concentrations 
47, 48
. Altogether, these 
observations suggest that corticosterone exacerbates atherosclerosis by primarily 
16 
 
upregulating circulating levels of total cholesterol and pro-atherogenic lipoproteins. 
Future studies including co-treatment of ApoE-deficient mice with corticosterone and 
inhibitors of cholesterol biosynthesis should provide new insights into this notion. 
Further, investigations combining pharmacological blockage of glucocorticoid receptor 
and either stress stimuli or corticosterone treatment are still desired to provide further 
insights into the mechanisms of action of glucocorticoids in the development of 
atherosclerosis.  
In summary, exposure to low levels of corticosterone for 13 weeks significantly 
exacerbated atherosclerosis in ApoE-deficient mice. This exacerbated phenotype was 
most likely driven by dyslipidaemia, without indications of increased systemic 
inflammation.  
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Figure legends 
Figure 1. Atherosclerotic plaque lesions in control mice (Con) and mice treated with 
corticosterone (CORT). A) Body weight progression during 13 weeks of intervention. 
B) Weekly food intake. C) Gatrocnemius muscle weight. D) Representative Oil Red O 
stained sections with respective enlarged pictures of atherosclerotic lesions (reference 
bar=100m). E) Quantification of atherosclerotic lesion area. Values represent mean ± 
18 
 
SE. ***P<0.001, *P<0.05. 
 
Figure 2. Circulating white blood cell numbers and serum cytokine levels in control 
mice (Con) and mice treated with corticosterone (CORT). A) Circulating white blood 
cell, neutrophil, lymphocyte, monocyte, eosinophil and basophil number. B) Serum 
IL-1β, IL-6 and CCL2 concentration. Values represent mean ± SE. *P<0.05. 
 
Figure. 3. Serum cholesterol and lipid protein profile of control mice (Con) and mice 
treated with corticosterone (CORT). Concentrations of total cholesterol (Total), 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density 
lipoprotein (VLDL), small dense low-density lipoprotein (sd-VLDL), triglyceride (TG), 
and chylomicron (CM) were analyzed by a HPLC based on-line
 
dual enzymatic method. 
Values represent mean ± SE. *P<0.05. 
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